Silfurberg
VC Fund
Reykjavík, Iceland
Silfurberg is an international venture capital firm that invests in early-stage health care, biotech, and other life science companies. The firm follows up its investments as an active participant in the company and aims all the time to add value to its investments whenever possible. Silfurberg was founded in 2002 and is based in Reykjavík,Iceland.
- Total investments:
- 4
- Last investment:
- Lead investor:
- 25%
Last updated:
For AI agents: llms.txt
Industries Silfurberg invests in
Stages Silfurberg invests in
Countries Silfurberg invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Investment Focus
Industry
- Biotechnology 2 (50%)
- Medical 1 (25%)
- Health Care 1 (25%)
- Life Science 1 (25%)
- Pharmaceutical 1 (25%)
Stage
- Seed 1 (25%)
- Series A 1 (25%)
- Series B 1 (25%)
- Series C 1 (25%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
| CFO | Total investments: 1 | Find email | ||
| CEO | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Axelyf is a biotechnology company that offers RNA medicines through safer and more effective lipid nanoparticle delivery. | $7.4M / Seed / Aug 07, 2025 | ||
| The Oculis drug delivery platform consists of a novel technique to facilitate drug absorption to both anterior and posterior parts of the eye. The advantage is a drug delivery system where diseases of the posterior part of the eye can be treated with a simple topical application. The Oculis drug delivery platform allows diseases such as DME(diabetic macular edema) at the posterior part of the eye to be treated with a non-invasive topical application. Furthermore, the technique has been demonstrated to allow diseases at the anterior part of the eye to be treated with a reduced number of topical applications compared to conventional eye-drops. | $57M / Series C / May 04, 2021 | ||
| The Oculis drug delivery platform consists of a novel technique to facilitate drug absorption to both anterior and posterior parts of the eye. The advantage is a drug delivery system where diseases of the posterior part of the eye can be treated with a simple topical application. The Oculis drug delivery platform allows diseases such as DME(diabetic macular edema) at the posterior part of the eye to be treated with a non-invasive topical application. Furthermore, the technique has been demonstrated to allow diseases at the anterior part of the eye to be treated with a reduced number of topical applications compared to conventional eye-drops. | $20.5M / Series B / Jan 04, 2018 | ||
| The Oculis drug delivery platform consists of a novel technique to facilitate drug absorption to both anterior and posterior parts of the eye. The advantage is a drug delivery system where diseases of the posterior part of the eye can be treated with a simple topical application. The Oculis drug delivery platform allows diseases such as DME(diabetic macular edema) at the posterior part of the eye to be treated with a non-invasive topical application. Furthermore, the technique has been demonstrated to allow diseases at the anterior part of the eye to be treated with a reduced number of topical applications compared to conventional eye-drops. | Series A / Aug 16, 2016 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Featured in Investor Lists
Recommended lists
FAQ
What does Silfurberg invest in?
Silfurberg invests primarily in Biotechnology, Medical and Health Care startups, most often at Seed and Series A stage. Most of the 4 investments tracked by Shizune back companies in Iceland. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Silfurberg?
Public channels for Silfurberg include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Silfurberg?
The team at Silfurberg includes Kristinn Palmason (CFO) and Friorik Steinn Kristjansson (CEO). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
